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330(3) if based solely on the brachial cuff measure-
ment of systolic pressure without taking into ac-
count the shape of the pressure waveform in
central and peripheral (i.e., brachial and/ or radial)
arteries. We have pressed this view (4) on the
European Society of Hypertension/European Society
of Cardiology committee (Yano et al. [1] reference
6) on the basis that elevated brachial and radial
systolic pressure in young persons (especially tall
male subjects) is caused by an exaggerated narrow
systolic pressure peak of the radial and brachial
pressure waves but a normal aortic pulse. This
contrasts with elevated systolic pressure (i.e., ISH)
in persons over age 60 years who almost invariably
have a much broader systolic peak, which is similar
in the aorta and upper limb arteries (Yano et al. [1]
reference 41).
On the basis of outcomes in the Chicago study,
one would ﬁnd it hard to justify a randomized study
of therapy compared with placebo in ISH of adult
male subjects <50 years of age. Another important
factor in guidelines, addressed by a cardiology
fellow in the same issue of the journal (5) is “patient
preference.” For the trivial difference in outcome at
20 years, would not most male subjects wish to defer
the stigma of disease, the expense, the inconve-
nience, and side effects of treatment for another
year or 2 until issues are clariﬁed? How are young
fellows (5) expected to include opinions, guidelines,
and patient preference in their discussions with
patients <50 years of age with ISH?*Michael F. O’Rourke, MD DSc
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REPLY: Interpreting Blood Pressure inYoung AdultsWe thank Dr. O’Rourke and colleagues for their in-
terest in our ﬁndings. Their comments are primarily
focused on how our ﬁndings can be translated into
practice or policy. We urge caution when extrapo-
lating epidemiological ﬁndings to clinical recom-
mendations. Research ﬁndings, especially those from
observational studies, need to be interpreted within
the context of global evidence. Unfortunately, evi-
dence is sparse pertaining to long-term outcomes in
younger adults with isolated systolic hypertension
(ISH). Considering the limited prognostic data on ISH
at younger ages, which our data begin to address, we
agree with the comment that it would be premature
and difﬁcult to conduct randomized intervention
trials in a population of younger individuals who
would be at low risk for events in the near term. We
suggest that the next major step is to replicate our
results in other studies with long-term follow-up of
younger adults (1,2).
The letter also addresses precision (personalized)
medicine. Execution of precision medicine in younger
adultswith ISHwill (partly) resolve concerns regarding
patient preference, unnecessary expense, and adverse
effects associated with treatments (3). ISH in younger
adults appears to be a heterogeneous condition; some
have higher stroke volume, whereas others have
higher aortic stiffness, or both (4). One size does not
seem to ﬁt all in the clinical management of ISH at
younger ages. The optimal means to identify higher-
risk groups among younger ISH patients merits
further research. Clinical characteristics (e.g., body
weight, diabetes), biomarkers (e.g., brain natriuretic
peptide), and out-of-ofﬁce blood pressure measure-
ment (e.g., home or ambulatorymonitoring) may serve
to identify higher-risk individuals. Rather than treat-
ing ISH in younger adults as a monolithic disease
and continuing to debate whether it is “pseudo” or
“spurious” hypertension, detailed phenotyping of
ISH patients based on (patho) physiology and global
context of risk for cardiovascular eventswould seem to
be most useful to assess an individual patient’s ex-
pected net beneﬁt from therapy.Yuichiro Yano, MD, PhD
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Revascularization in
Patients Undergoing
Primary Percutaneous
Coronary Intervention
for STEMIIs it Really What We Should Be Doing?We read with interest the work by Gershlick et al. (1),
which reported that in patients with ST-segment
elevation myocardial infarction and multivessel
coronary artery disease undergoing infarct-artery
percutaneous coronary intervention (PCI), complete
revascularization in noninfarct coronary arteries
with major stenoses signiﬁcantly reduces the risk of
adverse cardiovascular events, as compared with
PCI limited to the infarct-related artery. We feel the
management of the latter group (infarct-related artery
PCI only) was not per the current European Society of
Cardiology guideline (2), which recommends using
either a conservative (symptom-/noninvasive
ischemia–guided) strategy or a staged revasculariza-
tion approach (preferably fractional ﬂow reserve–
guided) performed several days or weeks after primary
percutaneous coronary intervention (PPCI). The meta-
analysis by Vlaar et al. (3) has clearly shown that when
signiﬁcant nonculprit vessel lesions are suitable for
PCI, they should only be treated during staged
procedures.Of the patients presenting with ST-segment
elevation myocardial infarction, 40% to 65% have
multivessel disease. The severity of nonculprit
stenosis can be overestimated during infarct angio-
graphy, potentially leading to inappropriate decision
making in a non-negligible number of patients (4).
In CvLPRIT (Complete Versus Lesion-Only Primary
PCI Trial), the bystander lesion was considered sig-
niﬁcant if stenosis was >70% in 1 angiographic view
or >50% in 2 views. If the latter cut-off was to be
applied to deﬁne multivessel disease, this could
lead to a large number of procedures, if complete
revascularization strategy was adopted, with an
inevitable major impact on the PPCI service provi-
sion. Adenosine stress cardiac magnetic resonance 1
to 5 days after ST-segment elevation myocardial
infarction is safe and can allow accurate detection of
signiﬁcant nonculprit territory stenosis. A recent
study by our group (5) demonstrated that <40% of
patients undergoing PPCI with moderate to severe
bystander nonculprit coronary artery disease need
further revascularization, when stress cardiac mag-
netic resonance was used as a gatekeeper to complete
revascularization.
We do not believe that the control group in
CvLPRIT reﬂects current practice. The question of
how and when best to deal with bystander lesions
detected during PPCI remains unanswered. We feel
that caution should be used in directly translating the
results of this trial in clinical practice, and in
considering immediate complete revascularization
merely on the presence of multivessel disease. In-
hospital invasive or noninvasive ischemia assess-
ment should perhaps play a greater role in the
decision making process, especially in the bystander
disease of moderate stenosis severity. A large ran-
domized study that is adequately powered for mor-
tality is immediately warranted to answer this.Amardeep Ghosh Dastidar, MBBS(Hons)
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